Literature DB >> 9392006

Characterization of new polyclonal antibodies specific for 40 and 42 amino acid-long amyloid beta peptides: their use to examine the cell biology of presenilins and the immunohistochemistry of sporadic Alzheimer's disease and cerebral amyloid angiopathy cases.

H Barelli1, A Lebeau, J Vizzavona, P Delaere, N Chevallier, C Drouot, P Marambaud, K Ancolio, J D Buxbaum, O Khorkova, J Heroux, S Sahasrabudhe, J Martinez, J M Warter, M Mohr, F Checler.   

Abstract

BACKGROUND: In Alzheimer's disease (AD), the main histological lesion is a proteinaceous deposit, the senile plaque, which is mainly composed of a peptide called A beta. The aggregation process is thought to occur through enhanced concentration of A beta 40 or increased production of the more readily aggregating 42 amino acid-long A beta 42 species.
MATERIALS AND METHODS: Specificity of the antibodies was assessed by dot blot, Western blot, ELISA, and immunoprecipitation procedures on synthetic and endogenous A beta produced by secreted HK293 cells. A beta and p3 production by wild-type and mutated presenilin 1-expressing cells transiently transfected with beta APP751 was monitored after metabolic labeling and immunoprecipitation procedures. Immunohistochemical analysis was performed on brains of sporadic and typical cerebrovascular amyloid angiopathy (CAA) cases.
RESULTS: Dot and Western blot analyses indicate that IgG-purified fractions of antisera recognize native and denaturated A beta s. FCA3340 and FCA 3542 display full specificity for A beta 40 and A beta 42, respectively. Antibodies immunoprecipitate their respective synthetic A beta species but also A beta s and their related p3 counterparts endogenously secreted by transfected human kidney 293 cells. This allowed us to show that mutations on presenilin 1 triggered similar increased ratios of A beta 42 and its p 342 counterpart over total A beta and p3. ELISA assays allow detection of about 25-50 pg/ml of A beta s and remain linear up to 750 to 1500 pg/ml without any cross-reactivity. FCA18 and FCA3542 label diffuse and mature plaques of a sporadic AD case whereas FCA3340 only reveals the mature lesions and particularly labels their central dense core. In a CAA case, FCA18 and FCA3340 reveal leptomeningeal and cortical arterioles whereas FCA3542 only faintly labels such structures.
CONCLUSIONS: Polyclonal antibodies exclusively recognizing A beta 40 (FCA 3340) or A beta 42 (FCA3542) were obtained. These demonstrated that FAD-linked presenilins similarly affect both p342 and A beta 42, suggesting that these mutations misroute the beta APP to a compartment where gamma-secretase, but not alpha-secretase, cleavages are modified. Overall, these antibodies should prove useful for fundamental and diagnostic approaches, as suggested by their usefulness for biochemical, cell biological, and immunohistochemical techniques.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9392006      PMCID: PMC2230230     

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  39 in total

1.  Tissue distribution of a novel neurotensin-degrading metallopeptidase. An immunological approach using monospecific polyclonal antibodies.

Authors:  F Checler; H Barelli; J P Vincent
Journal:  Biochem J       Date:  1989-01-15       Impact factor: 3.857

2.  Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa.

Authors:  H Schägger; G von Jagow
Journal:  Anal Biochem       Date:  1987-11-01       Impact factor: 3.365

3.  Examination of the role of endopeptidase 3.4.24.15 in A beta secretion by human transfected cells.

Authors:  N Chevallier; J Jiracek; B Vincent; C P Baur; M G Spillantini; M Goedert; V Dive; F Checler
Journal:  Br J Pharmacol       Date:  1997-06       Impact factor: 8.739

4.  Differences between vascular and plaque core amyloid in Alzheimer's disease.

Authors:  F Prelli; E Castaño; G G Glenner; B Frangione
Journal:  J Neurochem       Date:  1988-08       Impact factor: 5.372

5.  A p-methylbenzhydrylamine resin for improved solid-phase synthesis of peptide amides.

Authors:  G R Matsueda; J M Stewart
Journal:  Peptides       Date:  1981       Impact factor: 3.750

Review 6.  Molecular genetics of Alzheimer disease amyloid.

Authors:  R E Tanzi; P S George-Hyslop; J F Gusella
Journal:  J Biol Chem       Date:  1991-11-05       Impact factor: 5.157

Review 7.  Amyloid deposition as the central event in the aetiology of Alzheimer's disease.

Authors:  J Hardy; D Allsop
Journal:  Trends Pharmacol Sci       Date:  1991-10       Impact factor: 14.819

8.  Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs.

Authors:  D Burdick; B Soreghan; M Kwon; J Kosmoski; M Knauer; A Henschen; J Yates; C Cotman; C Glabe
Journal:  J Biol Chem       Date:  1992-01-05       Impact factor: 5.157

9.  Amyloid plaque core protein in Alzheimer disease and Down syndrome.

Authors:  C L Masters; G Simms; N A Weinman; G Multhaup; B L McDonald; K Beyreuther
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

10.  Protein chemical and immunocytochemical studies of meningovascular beta-amyloid protein in Alzheimer's disease and normal aging.

Authors:  C L Joachim; L K Duffy; J H Morris; D J Selkoe
Journal:  Brain Res       Date:  1988-11-22       Impact factor: 3.252

View more
  36 in total

1.  C-terminal maturation fragments of presenilin 1 and 2 control secretion of APP alpha and A beta by human cells and are degraded by proteasome.

Authors:  C A da Costa; K Ancolio; F Checler
Journal:  Mol Med       Date:  1999-03       Impact factor: 6.354

2.  Intraneuronal Abeta42 accumulation in human brain.

Authors:  G K Gouras; J Tsai; J Naslund; B Vincent; M Edgar; F Checler; J P Greenfield; V Haroutunian; J D Buxbaum; H Xu; P Greengard; N R Relkin
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

3.  Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the london mutant of human APP in neurons.

Authors:  J Van Dorpe; L Smeijers; I Dewachter; D Nuyens; K Spittaels; C Van Den Haute; M Mercken; D Moechars; I Laenen; C Kuiperi; K Bruynseels; I Tesseur; R Loos; H Vanderstichele; F Checler; R Sciot; F Van Leuven
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

Review 4.  Clinical-pathologic correlations in vascular cognitive impairment and dementia.

Authors:  Margaret Flanagan; Eric B Larson; Caitlin S Latimer; Brenna Cholerton; Paul K Crane; Kathleen S Montine; Lon R White; C Dirk Keene; Thomas J Montine
Journal:  Biochim Biophys Acta       Date:  2015-08-28

5.  Amyloid beta immunization worsens iron deposits in the choroid plexus and cerebral microbleeds.

Authors:  Nelly Joseph-Mathurin; Olène Dorieux; Stéphanie G Trouche; Allal Boutajangout; Audrey Kraska; Pascaline Fontès; Jean-Michel Verdier; Einar M Sigurdsson; Nadine Mestre-Francés; Marc Dhenain
Journal:  Neurobiol Aging       Date:  2013-06-22       Impact factor: 4.673

6.  Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer beta-amyloid peptides.

Authors:  J P Greenfield; J Tsai; G K Gouras; B Hai; G Thinakaran; F Checler; S S Sisodia; P Greengard; H Xu
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

7.  Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril formation.

Authors:  S R Hughes; O Khorkova; S Goyal; J Knaeblein; J Heroux; N G Riedel; S Sahasrabudhe
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

8.  Post-transcriptional contribution of a cAMP-dependent pathway to the formation of alpha- and beta/gamma-secretases-derived products of beta APP maturation in human cells expressing wild-type and Swedish mutated beta APP.

Authors:  P Marambaud; N Chevallier; K Ancolio; F Checler
Journal:  Mol Med       Date:  1998-11       Impact factor: 6.354

9.  Design and characterization of a new cell-permeant inhibitor of the beta-secretase BACE1.

Authors:  Solveig Lefranc-Jullien; Vincent Lisowski; Jean-François Hernandez; Jean Martinez; Frédéric Checler
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

Review 10.  Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease.

Authors:  S Hunter; C Brayne
Journal:  Mol Psychiatry       Date:  2017-11-07       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.